NSEPress Release29 Jul 2026 · 29 Jul 2026, 11:37 am
Press Release
Gland Pharma Limited · GLAND
✦ AI Summary▲ PositiveProduct Launch
Gland Pharma Limited has received approval for Sugammadex Injection 200 mg/2 mL and 500 mg/5 mL Single-Dose Vials from the United States Food and Drug Administration (FDA). The company has successfully launched the product on the market, with sales of over $11 billion for the month of April 2026. Gland Pharma was established in 1978 and has grown over the years to become one of the largest pharmaceutical companies in India, with a global presence in over 60 countries.
Analysis Scores
Earnings Impact8/10
Growth Catalyst9/10
Governance Concern1/10
Regulatory Risk2/10
Balance Sheet Risk1/10
Liquidity Impact9/10
Market Sentiment8/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Gland Pharma Limited has informed the Exchange regarding a press release dated July 29, 2026, titled "Gland Pharma receives approval for Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials".